Skip to content

Released Feb 28, 2022, after the close

10-K filed Feb 28, 2022, 59 days after period end · 0000950170-22-002293

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$17.07Mderived+7.4% vs Q4 2020+20.0% vs Q3 2021
Net Income-$68.62MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$69,382,000N/M
Operating Cash Flowderived-$70,293,000N/M
Free Cash Flowderived-$88,662,000N/M
Margins · derived
Operating margin-406.5%−196.4 pt vs Q4 2020
Net margin-402.1%−68.0 pt vs Q4 2020

What the release said

The release

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019Q4 2018
Revenue$17.07M$15.90M$2.80M$1.66M
Net Income-$68.62M-$53.11M-$28.30M-$16.03M
EPS Diluted——-$0.37-$0.25

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR